id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-313984-7wvfnag1	Remy, Kenneth E	Immunotherapies for COVID-19: lessons learned from sepsis	2020-04-28		.txt	text/plain	2174	108	39	Although more recent controlled studies indicate that plasma IL-6 concentrations can be in the range seen in bacterial infections, the time course of change is very different; in some cases, concentrations in patients with coronavirus disease 2019 (COVID-19) seem to increase over time with illness severity and worsening lung function. Indeed, when measured in patients infected with SARS-CoV-2, IL-10 concentrations (the most immunosuppressant cytokine in the body) are also elevated, which might lead to a different conclusion for therapeutic approaches and in understanding the disease pathophysiology. In particular, the modest inflammatory response and the progressive and profound suppression of adaptive immunity in COVID-19 relative to sepsis argues for perhaps a different therapeutic approach. However, if SARS-CoV-2 infection is similar to other chronic inflammatory and immune suppressive diseases, such as sepsis, we argue that immune stimulants, and not anti-inflammatory agents, should be considered as the first-line treatment option.	./cache/cord-313984-7wvfnag1.txt	./txt/cord-313984-7wvfnag1.txt